<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: The study aim was to evaluate the efficacy and safety of initial combination therapy with saxagliptin + <z:chebi fb="0" ids="6801">metformin</z:chebi> vs. saxagliptin or <z:chebi fb="0" ids="6801">metformin</z:chebi> monotherapy in treatment-naïve patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (T2D) and inadequate glycaemic control </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: In this multicentre, randomized, double-blind, active-controlled phase 3 trial, 1306 treatment-naïve patients with T2D &gt;or=18 to &lt;or=77 years, glycosylated <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> (HbA1c) &gt;or=8 to &lt;or=12%, fasting C-<z:chebi fb="7" ids="16670">peptide</z:chebi> concentration &gt;or=1.0 ng/ml, body mass index &lt;or=40 kg/m(2) were randomized to receive saxagliptin 5 mg + <z:chebi fb="0" ids="6801">metformin</z:chebi> 500 mg, saxagliptin 10 mg + <z:chebi fb="0" ids="6801">metformin</z:chebi> 500 mg, saxagliptin 10 mg + placebo or <z:chebi fb="0" ids="6801">metformin</z:chebi> 500 mg + placebo for 24 weeks </plain></SENT>
<SENT sid="2" pm="."><plain>From weeks 1-5, <z:chebi fb="0" ids="6801">metformin</z:chebi> was uptitrated in 500-mg/day increments to 2000 mg/day maximum in the saxagliptin 5 mg + <z:chebi fb="0" ids="6801">metformin</z:chebi>, saxagliptin 10 mg + <z:chebi fb="0" ids="6801">metformin</z:chebi> and <z:chebi fb="0" ids="6801">metformin</z:chebi> + placebo treatment groups </plain></SENT>
<SENT sid="3" pm="."><plain>The main outcome measure was HbA1c change from baseline to week 24 </plain></SENT>
<SENT sid="4" pm="."><plain>Selected secondary outcomes included change from baseline to week 24 in fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> (FPG), proportion of patients achieving HbA1c &lt;7% and postprandial <z:chebi fb="105" ids="17234">glucose</z:chebi> area under the curve (<z:chebi fb="73" ids="53262">PPG</z:chebi>-AUC) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: At 24 weeks, saxagliptin 5 mg + <z:chebi fb="0" ids="6801">metformin</z:chebi> and saxagliptin 10 mg + <z:chebi fb="0" ids="6801">metformin</z:chebi> demonstrated statistically significant adjusted mean decreases vs. saxagliptin 10 mg and <z:chebi fb="0" ids="6801">metformin</z:chebi> monotherapies in HbA1c (-2.5 and -2.5% vs. -1.7 and -2.0%, <z:hpo ids='HP_0000001'>all</z:hpo> p &lt; 0.0001 vs. monotherapy) and FPG (-60 and -62 mg/dl vs. -31 and -47 mg/dl, both p &lt; 0.0001 vs. saxagliptin 10 mg; p = 0.0002 saxagliptin 5 mg + <z:chebi fb="0" ids="6801">metformin</z:chebi> vs. <z:chebi fb="0" ids="6801">metformin</z:chebi>; p &lt; 0.0001 saxagliptin 10 mg + <z:chebi fb="0" ids="6801">metformin</z:chebi> vs. <z:chebi fb="0" ids="6801">metformin</z:chebi>) </plain></SENT>
<SENT sid="6" pm="."><plain>Proportion of patients achieving an HbA1c &lt;7% was 60.3 and 59.7%, respectively, for saxagliptin 5 mg + <z:chebi fb="0" ids="6801">metformin</z:chebi> and saxagliptin 10 mg + <z:chebi fb="0" ids="6801">metformin</z:chebi> (<z:hpo ids='HP_0000001'>all</z:hpo> p &lt; 0.0001 vs. monotherapy) </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="73" ids="53262">PPG</z:chebi>-AUC was significantly reduced [-21,080 mg x min/dl (saxagliptin 5 mg + <z:chebi fb="0" ids="6801">metformin</z:chebi>) and -21,336 mg x min/dl (saxagliptin 10 mg + <z:chebi fb="0" ids="6801">metformin</z:chebi>) vs. -16,054 mg x min/dl (saxagliptin 10 mg) and -15,005 mg x min/dl (<z:chebi fb="0" ids="6801">metformin</z:chebi>), <z:hpo ids='HP_0000001'>all</z:hpo> p &lt; 0.0001 vs. monotherapy] </plain></SENT>
<SENT sid="8" pm="."><plain>Adverse event occurrence was similar across <z:hpo ids='HP_0000001'>all</z:hpo> groups </plain></SENT>
<SENT sid="9" pm="."><plain>Hypoglycaemic events were infrequent </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: Saxagliptin + <z:chebi fb="0" ids="6801">metformin</z:chebi> as initial therapy led to statistically significant improvements compared with either treatment alone across key glycaemic parameters with a tolerability profile similar to the monotherapy components </plain></SENT>
</text></document>